|Articles|October 25, 2013

No Wall Street Crash for Biotech

When Warren Buffet was ten, he made his first trip to NYC. What did he want to do? “See the Stock Exchange,” he told a news reporter on TV yesterday.

When Warren Buffet was ten, he made his first trip to NYC. What did he want to do? “See the Stock Exchange,”  he told a news reporter on TV yesterday. “It is the epicenter of Capitalization.” Buffet claims he feels exactly the same excitement today as he did then as a ten year old whenever he visits the Floor.  He was in NYC to promote his son Peter’s book, “Life is What You Make It.”

This month, of course, marks the anniversary of The Wall Street Crash of 1929, the most devastating stock market crash in the history of the United States. The crash signaled the beginning of the 10-year Great Depression that affected all Western industrialized countries. We’re holding our breath, but so far it looks like clear sailing with no October surprises in store, especially for biotech.

As of yesterday, the 10 Best Biotech Stocks for 2013 were looking like this. (Source: TheStreet Ratings


Related to this article

Pharmaceutical Executive daily
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
Pharmaceutical executive daily
InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.